logo-education
0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

Forgotten your password?

Income Generation – a hot topic for academy converters

21 May 2012

A recent survey conducted by Ipsos Mori on behalf of Browne Jacobson LLP shows that 40% of head teachers wish they had invested more time in considering income generation opportunities when converting from a maintained school to an academy.

Academy status gives schools freedom from LA control enabling them to decide how best to manage their resources rather than having those decisions made for them. Some schools are pro-actively reviewing their policies and procedures to ensure that assets such as sports halls and playing fields are utilised to their full potential to yield new income streams.

However, schools need to take care before entering into significant contracts with outside entities. The ability for academies to engage in commercial activities, the risk involved and tax implications are just some of the reasons why professional advice and guidance is needed. Failure to take appropriate advice could leave some academies in a tricky situation.

Related opinions

Does the move into Step 4 mean the ending of Covid-19 restrictions within schools?

With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.

View blog

Advocacy in Action: Female Genital Mutilation Protection Orders (FGMPO)

The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.

View blog

Responsibilities towards students identifying as non-binary

Our top tips for supporting transgender and non-binary pupils.

View blog

Schools face scrutiny over Covid-19 vaccinations for children

On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.

View blog

Mailing list sign up

Select which mailings you would like to receive from us.

Sign up